C1-inhibitor therapy for hereditary angioedema attacks: Prospective patient assessments of health-related quality of life

Againdra K. Bewtra, Robyn J. Levy, Kraig W. Jacobson, Richard L. Wasserman, Thomas Machnig, Timothy J. Craig

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

C1-inhibitor (INH) concentrate, which is recommended as first-line treatment for acute hereditary angioedema (HAE) attacks in many countries, was recently approved in the United States. We sought to solicit patients' feedback about their health-related quality of life (HRQoL) while being treated with C1-INH concentrate for acute HAE attacks under real-world conditions, as well as the personal impact of the availability of C1-INH on lifestyle and mental health domains. Subjects enrolled in an open-label study of C1-INH at 20 U/kg for acute HAE attacks were invited to participate in a prospectively designed survey to solicit "real-time" patient responses that were collected via an interactive voice response service or online with a personal computer. Eighteen subjects submitted 60 quarterly HRQoL and treatment impact survey responses over 29 months. Seventeen of 18 patients responding reported mean short form 12 HRQoL scores that were within a normal range. More than one-half indicated that C1-INH availability made them feel somewhat or much better, and >80% reported having a better outlook on the future and feeling more secure about the danger of life-threatening attacks. These data confirm a high level of HRQoL and a positive impact in lifestyle and emotional domains among patients who were treated for acute attacks of HAE with C1-INH concentrate.

Original languageEnglish
Pages (from-to)427-431
Number of pages5
JournalAllergy and Asthma Proceedings
Volume33
Issue number5
DOIs
StatePublished - Sep 2012

Fingerprint

Hereditary Angioedemas
Quality of Life
Life Style
Microcomputers
Therapeutics
Health Status
Mental Health
Emotions
Reference Values
Surveys and Questionnaires

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine

Cite this

C1-inhibitor therapy for hereditary angioedema attacks : Prospective patient assessments of health-related quality of life. / Bewtra, Againdra K.; Levy, Robyn J.; Jacobson, Kraig W.; Wasserman, Richard L.; Machnig, Thomas; Craig, Timothy J.

In: Allergy and Asthma Proceedings, Vol. 33, No. 5, 09.2012, p. 427-431.

Research output: Contribution to journalArticle

Bewtra, Againdra K. ; Levy, Robyn J. ; Jacobson, Kraig W. ; Wasserman, Richard L. ; Machnig, Thomas ; Craig, Timothy J. / C1-inhibitor therapy for hereditary angioedema attacks : Prospective patient assessments of health-related quality of life. In: Allergy and Asthma Proceedings. 2012 ; Vol. 33, No. 5. pp. 427-431.
@article{cc7c8ff58fac407ba8a613cf5c27955f,
title = "C1-inhibitor therapy for hereditary angioedema attacks: Prospective patient assessments of health-related quality of life",
abstract = "C1-inhibitor (INH) concentrate, which is recommended as first-line treatment for acute hereditary angioedema (HAE) attacks in many countries, was recently approved in the United States. We sought to solicit patients' feedback about their health-related quality of life (HRQoL) while being treated with C1-INH concentrate for acute HAE attacks under real-world conditions, as well as the personal impact of the availability of C1-INH on lifestyle and mental health domains. Subjects enrolled in an open-label study of C1-INH at 20 U/kg for acute HAE attacks were invited to participate in a prospectively designed survey to solicit {"}real-time{"} patient responses that were collected via an interactive voice response service or online with a personal computer. Eighteen subjects submitted 60 quarterly HRQoL and treatment impact survey responses over 29 months. Seventeen of 18 patients responding reported mean short form 12 HRQoL scores that were within a normal range. More than one-half indicated that C1-INH availability made them feel somewhat or much better, and >80{\%} reported having a better outlook on the future and feeling more secure about the danger of life-threatening attacks. These data confirm a high level of HRQoL and a positive impact in lifestyle and emotional domains among patients who were treated for acute attacks of HAE with C1-INH concentrate.",
author = "Bewtra, {Againdra K.} and Levy, {Robyn J.} and Jacobson, {Kraig W.} and Wasserman, {Richard L.} and Thomas Machnig and Craig, {Timothy J.}",
year = "2012",
month = "9",
doi = "10.2500/aap.2012.33.3597",
language = "English",
volume = "33",
pages = "427--431",
journal = "Allergy and Asthma Proceedings",
issn = "1088-5412",
publisher = "OceanSide Publications Inc.",
number = "5",

}

TY - JOUR

T1 - C1-inhibitor therapy for hereditary angioedema attacks

T2 - Prospective patient assessments of health-related quality of life

AU - Bewtra, Againdra K.

AU - Levy, Robyn J.

AU - Jacobson, Kraig W.

AU - Wasserman, Richard L.

AU - Machnig, Thomas

AU - Craig, Timothy J.

PY - 2012/9

Y1 - 2012/9

N2 - C1-inhibitor (INH) concentrate, which is recommended as first-line treatment for acute hereditary angioedema (HAE) attacks in many countries, was recently approved in the United States. We sought to solicit patients' feedback about their health-related quality of life (HRQoL) while being treated with C1-INH concentrate for acute HAE attacks under real-world conditions, as well as the personal impact of the availability of C1-INH on lifestyle and mental health domains. Subjects enrolled in an open-label study of C1-INH at 20 U/kg for acute HAE attacks were invited to participate in a prospectively designed survey to solicit "real-time" patient responses that were collected via an interactive voice response service or online with a personal computer. Eighteen subjects submitted 60 quarterly HRQoL and treatment impact survey responses over 29 months. Seventeen of 18 patients responding reported mean short form 12 HRQoL scores that were within a normal range. More than one-half indicated that C1-INH availability made them feel somewhat or much better, and >80% reported having a better outlook on the future and feeling more secure about the danger of life-threatening attacks. These data confirm a high level of HRQoL and a positive impact in lifestyle and emotional domains among patients who were treated for acute attacks of HAE with C1-INH concentrate.

AB - C1-inhibitor (INH) concentrate, which is recommended as first-line treatment for acute hereditary angioedema (HAE) attacks in many countries, was recently approved in the United States. We sought to solicit patients' feedback about their health-related quality of life (HRQoL) while being treated with C1-INH concentrate for acute HAE attacks under real-world conditions, as well as the personal impact of the availability of C1-INH on lifestyle and mental health domains. Subjects enrolled in an open-label study of C1-INH at 20 U/kg for acute HAE attacks were invited to participate in a prospectively designed survey to solicit "real-time" patient responses that were collected via an interactive voice response service or online with a personal computer. Eighteen subjects submitted 60 quarterly HRQoL and treatment impact survey responses over 29 months. Seventeen of 18 patients responding reported mean short form 12 HRQoL scores that were within a normal range. More than one-half indicated that C1-INH availability made them feel somewhat or much better, and >80% reported having a better outlook on the future and feeling more secure about the danger of life-threatening attacks. These data confirm a high level of HRQoL and a positive impact in lifestyle and emotional domains among patients who were treated for acute attacks of HAE with C1-INH concentrate.

UR - http://www.scopus.com/inward/record.url?scp=84866772079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866772079&partnerID=8YFLogxK

U2 - 10.2500/aap.2012.33.3597

DO - 10.2500/aap.2012.33.3597

M3 - Article

C2 - 23026185

AN - SCOPUS:84866772079

VL - 33

SP - 427

EP - 431

JO - Allergy and Asthma Proceedings

JF - Allergy and Asthma Proceedings

SN - 1088-5412

IS - 5

ER -